Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endocrinology | 35 | 2023 | 442 | 10.680 |
Why?
|
Diabetes Mellitus, Type 2 | 107 | 2024 | 12159 | 7.850 |
Why?
|
Hypoglycemic Agents | 81 | 2024 | 3089 | 7.480 |
Why?
|
Diabetes Mellitus | 46 | 2023 | 5842 | 5.370 |
Why?
|
Glucagon-Like Peptides | 21 | 2023 | 153 | 5.180 |
Why?
|
Reference Standards | 35 | 2023 | 1005 | 3.170 |
Why?
|
Standard of Care | 35 | 2023 | 550 | 3.130 |
Why?
|
Metformin | 23 | 2023 | 910 | 3.000 |
Why?
|
Peptides | 17 | 2022 | 4353 | 2.180 |
Why?
|
Blood Glucose | 48 | 2024 | 6392 | 1.950 |
Why?
|
Societies, Medical | 35 | 2023 | 3923 | 1.750 |
Why?
|
Insulin, Long-Acting | 7 | 2023 | 58 | 1.690 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2021 | 90 | 1.530 |
Why?
|
Prediabetic State | 8 | 2019 | 546 | 1.330 |
Why?
|
Cardiovascular Diseases | 21 | 2024 | 15521 | 1.240 |
Why?
|
Venoms | 4 | 2017 | 94 | 1.180 |
Why?
|
Incretins | 3 | 2019 | 99 | 1.080 |
Why?
|
Body Weight | 19 | 2023 | 4618 | 1.050 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 5 | 2024 | 311 | 1.050 |
Why?
|
Diabetic Angiopathies | 4 | 2024 | 805 | 0.910 |
Why?
|
Hypoglycemia | 12 | 2021 | 883 | 0.870 |
Why?
|
Polycystic Ovary Syndrome | 6 | 2020 | 376 | 0.810 |
Why?
|
Drug Combinations | 13 | 2023 | 2048 | 0.810 |
Why?
|
Glucose Intolerance | 3 | 2020 | 575 | 0.810 |
Why?
|
Hyperglycemia | 6 | 2022 | 1375 | 0.800 |
Why?
|
Insulin | 17 | 2024 | 6588 | 0.790 |
Why?
|
Immunoglobulin Fc Fragments | 6 | 2023 | 282 | 0.770 |
Why?
|
Receptors, Glucagon | 2 | 2012 | 90 | 0.770 |
Why?
|
Glucagon-Like Peptide 1 | 7 | 2024 | 364 | 0.750 |
Why?
|
Humans | 168 | 2024 | 761222 | 0.730 |
Why?
|
Duodenum | 1 | 2024 | 491 | 0.720 |
Why?
|
Cholecalciferol | 3 | 2019 | 552 | 0.680 |
Why?
|
Retinal Diseases | 2 | 2023 | 705 | 0.640 |
Why?
|
Pancreatitis | 2 | 2023 | 1081 | 0.570 |
Why?
|
Thiazolidinediones | 6 | 2013 | 460 | 0.570 |
Why?
|
Risk Reduction Behavior | 5 | 2021 | 1111 | 0.560 |
Why?
|
Gastrointestinal Diseases | 2 | 2023 | 1201 | 0.540 |
Why?
|
Diabetes Complications | 2 | 2018 | 1316 | 0.530 |
Why?
|
Recombinant Fusion Proteins | 6 | 2023 | 3726 | 0.490 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 10218 | 0.490 |
Why?
|
Obesity | 17 | 2024 | 12940 | 0.480 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2016 | 118 | 0.480 |
Why?
|
Clinical Trials as Topic | 3 | 2022 | 8002 | 0.450 |
Why?
|
Bariatric Surgery | 1 | 2024 | 991 | 0.450 |
Why?
|
Diabetic Retinopathy | 1 | 2023 | 1276 | 0.440 |
Why?
|
Life Style | 6 | 2021 | 3907 | 0.440 |
Why?
|
Managed Care Programs | 1 | 2018 | 937 | 0.420 |
Why?
|
Intestinal Mucosa | 1 | 2024 | 3031 | 0.420 |
Why?
|
Treatment Outcome | 25 | 2024 | 64681 | 0.400 |
Why?
|
Weight Loss | 10 | 2020 | 2680 | 0.400 |
Why?
|
Sulfonylurea Compounds | 4 | 2020 | 219 | 0.390 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2023 | 2254 | 0.380 |
Why?
|
Spectrometry, Fluorescence | 2 | 2013 | 683 | 0.380 |
Why?
|
Anaphylaxis | 3 | 2024 | 758 | 0.360 |
Why?
|
Double-Blind Method | 12 | 2023 | 12341 | 0.360 |
Why?
|
Forearm | 1 | 2013 | 427 | 0.350 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2021 | 3417 | 0.340 |
Why?
|
Preventive Health Services | 2 | 2018 | 567 | 0.330 |
Why?
|
Middle Aged | 52 | 2024 | 220858 | 0.330 |
Why?
|
Glucose | 7 | 2024 | 4342 | 0.330 |
Why?
|
Sodium-Glucose Transporter 2 | 3 | 2022 | 89 | 0.320 |
Why?
|
Advisory Committees | 1 | 2013 | 788 | 0.320 |
Why?
|
Drug Therapy, Combination | 9 | 2020 | 6304 | 0.320 |
Why?
|
Female | 66 | 2024 | 392552 | 0.300 |
Why?
|
Social Environment | 1 | 2013 | 1022 | 0.300 |
Why?
|
Patient Selection | 2 | 2023 | 4246 | 0.300 |
Why?
|
Insulin Resistance | 6 | 2020 | 3952 | 0.290 |
Why?
|
Adult | 49 | 2024 | 221120 | 0.270 |
Why?
|
Anemia | 1 | 2016 | 1504 | 0.270 |
Why?
|
Administration, Oral | 5 | 2023 | 4015 | 0.260 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2019 | 858 | 0.260 |
Why?
|
Male | 55 | 2024 | 360703 | 0.260 |
Why?
|
Aged | 36 | 2024 | 169292 | 0.260 |
Why?
|
Sex Hormone-Binding Globulin | 2 | 2020 | 550 | 0.250 |
Why?
|
Androgens | 3 | 2018 | 1283 | 0.250 |
Why?
|
Diabetes, Gestational | 1 | 2015 | 1250 | 0.240 |
Why?
|
Gonadal Steroid Hormones | 1 | 2008 | 702 | 0.240 |
Why?
|
Models, Statistical | 1 | 2019 | 5081 | 0.240 |
Why?
|
Comorbidity | 5 | 2023 | 10516 | 0.240 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4851 | 0.220 |
Why?
|
Body Mass Index | 8 | 2019 | 12952 | 0.210 |
Why?
|
Skin | 3 | 2013 | 4473 | 0.200 |
Why?
|
Adiponectin | 2 | 2007 | 1107 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2020 | 10756 | 0.200 |
Why?
|
Adipocytes | 3 | 2008 | 1190 | 0.200 |
Why?
|
Caprylates | 1 | 2022 | 115 | 0.190 |
Why?
|
Primary Prevention | 2 | 2023 | 1185 | 0.190 |
Why?
|
Electronic Health Records | 1 | 2019 | 4822 | 0.190 |
Why?
|
Placebos | 2 | 2020 | 1666 | 0.190 |
Why?
|
Delayed-Action Preparations | 2 | 2017 | 961 | 0.190 |
Why?
|
Fasting | 2 | 2018 | 1603 | 0.180 |
Why?
|
Cardiology | 2 | 2022 | 1693 | 0.180 |
Why?
|
Sodium | 2 | 2022 | 1589 | 0.170 |
Why?
|
Postprandial Period | 2 | 2019 | 314 | 0.170 |
Why?
|
Overweight | 4 | 2023 | 2418 | 0.170 |
Why?
|
Clusterin | 1 | 2020 | 71 | 0.170 |
Why?
|
Anti-Obesity Agents | 2 | 2017 | 227 | 0.170 |
Why?
|
Glucosides | 2 | 2020 | 512 | 0.160 |
Why?
|
Fluorescence | 2 | 2012 | 751 | 0.160 |
Why?
|
Diabetic Ketoacidosis | 1 | 2022 | 253 | 0.160 |
Why?
|
Remission Induction | 1 | 2024 | 2392 | 0.150 |
Why?
|
Stroke | 2 | 2020 | 9721 | 0.150 |
Why?
|
Heart Failure | 2 | 2021 | 11701 | 0.150 |
Why?
|
Estrogens | 2 | 2015 | 1522 | 0.150 |
Why?
|
Dietary Supplements | 3 | 2019 | 3410 | 0.150 |
Why?
|
Insulin Infusion Systems | 1 | 2019 | 217 | 0.140 |
Why?
|
Mass Screening | 1 | 2013 | 5426 | 0.140 |
Why?
|
Energy Intake | 2 | 2017 | 2133 | 0.140 |
Why?
|
Hypolipidemic Agents | 1 | 2022 | 609 | 0.140 |
Why?
|
Injections, Subcutaneous | 1 | 2019 | 672 | 0.140 |
Why?
|
Women's Health | 3 | 2017 | 2070 | 0.140 |
Why?
|
Glucose Tolerance Test | 3 | 2011 | 1178 | 0.140 |
Why?
|
Benzhydryl Compounds | 2 | 2020 | 917 | 0.140 |
Why?
|
Nausea | 3 | 2019 | 678 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 709 | 0.140 |
Why?
|
Glucose Clamp Technique | 3 | 2020 | 262 | 0.140 |
Why?
|
Risk Factors | 16 | 2023 | 74241 | 0.140 |
Why?
|
Coronary Artery Disease | 4 | 2018 | 6506 | 0.140 |
Why?
|
Drug Substitution | 1 | 2019 | 291 | 0.140 |
Why?
|
Menstruation Disturbances | 1 | 2018 | 143 | 0.140 |
Why?
|
Disasters | 1 | 2022 | 520 | 0.130 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2017 | 129 | 0.130 |
Why?
|
Glucose Metabolism Disorders | 1 | 2016 | 52 | 0.130 |
Why?
|
Glycemic Index | 1 | 2018 | 396 | 0.130 |
Why?
|
Muscle, Skeletal | 4 | 2020 | 4947 | 0.130 |
Why?
|
Reproductive History | 1 | 2017 | 210 | 0.130 |
Why?
|
Gastric Bypass | 1 | 2024 | 818 | 0.120 |
Why?
|
Acute Disease | 2 | 2023 | 7226 | 0.120 |
Why?
|
Menstruation | 1 | 2017 | 307 | 0.120 |
Why?
|
Drug Labeling | 1 | 2017 | 248 | 0.120 |
Why?
|
Blood Glucose Self-Monitoring | 3 | 2023 | 468 | 0.110 |
Why?
|
Delivery of Health Care | 2 | 2024 | 5333 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 590 | 0.110 |
Why?
|
Time Factors | 7 | 2023 | 39957 | 0.110 |
Why?
|
Neurotoxicity Syndromes | 1 | 2017 | 301 | 0.110 |
Why?
|
Vitamin B 12 | 1 | 2016 | 524 | 0.100 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2017 | 602 | 0.100 |
Why?
|
Homocysteine | 1 | 2016 | 637 | 0.100 |
Why?
|
United States | 13 | 2024 | 72341 | 0.100 |
Why?
|
Adiposity | 1 | 2022 | 1879 | 0.100 |
Why?
|
Disease Management | 1 | 2023 | 2507 | 0.100 |
Why?
|
Allylamine | 1 | 2011 | 10 | 0.100 |
Why?
|
Evidence-Based Medicine | 1 | 2024 | 3691 | 0.100 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2019 | 0.100 |
Why?
|
Aspirin | 1 | 2023 | 3129 | 0.100 |
Why?
|
Incidence | 7 | 2018 | 21366 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3881 | 0.100 |
Why?
|
Antibody Formation | 1 | 2016 | 1391 | 0.090 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2011 | 91 | 0.090 |
Why?
|
Dietary Sucrose | 1 | 2013 | 243 | 0.090 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1331 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6486 | 0.090 |
Why?
|
Risk | 4 | 2018 | 9616 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1634 | 0.090 |
Why?
|
Health Status | 1 | 2023 | 4077 | 0.090 |
Why?
|
Kidney Diseases | 1 | 2021 | 2092 | 0.090 |
Why?
|
Quality Improvement | 2 | 2023 | 3808 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3200 | 0.090 |
Why?
|
Polyneuropathies | 1 | 2011 | 137 | 0.080 |
Why?
|
Atherosclerosis | 2 | 2023 | 3407 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2024 | 80675 | 0.080 |
Why?
|
Pregnancy | 3 | 2023 | 29893 | 0.080 |
Why?
|
Postmenopause | 2 | 2017 | 2514 | 0.080 |
Why?
|
Body Water | 1 | 2009 | 340 | 0.080 |
Why?
|
Microspheres | 1 | 2011 | 783 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2019 | 5250 | 0.080 |
Why?
|
Vomiting | 1 | 2011 | 650 | 0.070 |
Why?
|
Antibodies | 1 | 2016 | 2415 | 0.070 |
Why?
|
Vitamin D | 2 | 2019 | 3301 | 0.070 |
Why?
|
Aged, 80 and over | 5 | 2022 | 58952 | 0.070 |
Why?
|
Veterans | 1 | 2021 | 2656 | 0.070 |
Why?
|
Metabolic Diseases | 1 | 2014 | 680 | 0.070 |
Why?
|
Estrogen Replacement Therapy | 1 | 2014 | 1208 | 0.070 |
Why?
|
Diabetic Neuropathies | 1 | 2011 | 406 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2019 | 3608 | 0.070 |
Why?
|
Autonomic Nervous System | 1 | 2011 | 704 | 0.060 |
Why?
|
Testosterone | 1 | 2016 | 2472 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2023 | 7804 | 0.060 |
Why?
|
Exercise | 2 | 2019 | 5874 | 0.060 |
Why?
|
Thyroid Gland | 1 | 2011 | 1169 | 0.060 |
Why?
|
Body Composition | 2 | 2011 | 2427 | 0.060 |
Why?
|
Anticholesteremic Agents | 1 | 2011 | 968 | 0.060 |
Why?
|
Comparative Effectiveness Research | 2 | 2020 | 708 | 0.060 |
Why?
|
Calcium | 1 | 2017 | 5719 | 0.060 |
Why?
|
Patient Preference | 1 | 2011 | 927 | 0.060 |
Why?
|
Motor Activity | 1 | 2013 | 2712 | 0.050 |
Why?
|
Research Design | 1 | 2019 | 6180 | 0.050 |
Why?
|
Adolescent | 6 | 2024 | 88300 | 0.050 |
Why?
|
Biomedical Research | 1 | 2018 | 3434 | 0.050 |
Why?
|
Consensus | 2 | 2022 | 3134 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2017 | 39127 | 0.050 |
Why?
|
Cholesterol, LDL | 1 | 2011 | 2380 | 0.050 |
Why?
|
Amyloid | 1 | 2007 | 848 | 0.050 |
Why?
|
Cohort Studies | 6 | 2024 | 41496 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15308 | 0.050 |
Why?
|
Animals | 5 | 2024 | 168089 | 0.050 |
Why?
|
Diet | 1 | 2019 | 8048 | 0.050 |
Why?
|
Liver | 2 | 2020 | 7512 | 0.050 |
Why?
|
Cardiology Service, Hospital | 1 | 2022 | 240 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26072 | 0.040 |
Why?
|
Aging | 1 | 2018 | 8702 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 790 | 0.040 |
Why?
|
Child | 4 | 2023 | 80154 | 0.040 |
Why?
|
Review Literature as Topic | 1 | 2021 | 348 | 0.040 |
Why?
|
Policy | 1 | 2022 | 506 | 0.040 |
Why?
|
Genomics | 1 | 2014 | 5829 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7386 | 0.040 |
Why?
|
Chromaffin Cells | 1 | 1998 | 10 | 0.040 |
Why?
|
Biopsy | 2 | 2007 | 6781 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2019 | 555 | 0.040 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2005 | 1933 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2020 | 883 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 819 | 0.040 |
Why?
|
Chromogranins | 1 | 1998 | 160 | 0.040 |
Why?
|
Sex Factors | 2 | 2024 | 10553 | 0.030 |
Why?
|
Catecholamines | 1 | 1998 | 387 | 0.030 |
Why?
|
Young Adult | 3 | 2020 | 59222 | 0.030 |
Why?
|
Depression | 1 | 2016 | 8132 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1039 | 0.030 |
Why?
|
Exocytosis | 1 | 1998 | 320 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1504 | 0.030 |
Why?
|
Genetic Loci | 2 | 2017 | 2623 | 0.030 |
Why?
|
Receptor, Insulin | 1 | 2020 | 836 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2022 | 846 | 0.030 |
Why?
|
Databases, Factual | 2 | 2021 | 7965 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 413 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1651 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3423 | 0.030 |
Why?
|
Acetylcholine | 1 | 1998 | 629 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3727 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2021 | 2082 | 0.030 |
Why?
|
Melanoma | 1 | 2013 | 5694 | 0.030 |
Why?
|
Apolipoprotein C-I | 1 | 2014 | 13 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2017 | 628 | 0.030 |
Why?
|
Patient Dropouts | 1 | 2017 | 411 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 1995 | 302 | 0.030 |
Why?
|
Age Factors | 3 | 2018 | 18384 | 0.030 |
Why?
|
Physician's Role | 1 | 2021 | 920 | 0.030 |
Why?
|
Acetylcysteine | 1 | 1995 | 260 | 0.030 |
Why?
|
Weight Gain | 1 | 2004 | 2349 | 0.030 |
Why?
|
Apolipoproteins A | 1 | 2014 | 95 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2017 | 485 | 0.030 |
Why?
|
Lipoprotein Lipase | 1 | 2014 | 133 | 0.030 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2014 | 152 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5809 | 0.030 |
Why?
|
Menarche | 1 | 2017 | 532 | 0.030 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2014 | 113 | 0.030 |
Why?
|
Genetic Pleiotropy | 1 | 2014 | 181 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2643 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2023 | 2317 | 0.030 |
Why?
|
Nicotine | 1 | 1998 | 678 | 0.030 |
Why?
|
Prospective Studies | 4 | 2022 | 54437 | 0.030 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2014 | 276 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2020 | 2329 | 0.030 |
Why?
|
Pandemics | 2 | 2022 | 8663 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2019 | 1723 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 713 | 0.020 |
Why?
|
Safety | 1 | 2016 | 1151 | 0.020 |
Why?
|
Waist Circumference | 1 | 2015 | 933 | 0.020 |
Why?
|
Disease Progression | 1 | 2008 | 13511 | 0.020 |
Why?
|
Health Behavior | 1 | 2023 | 2641 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2003 | 3313 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12474 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 14025 | 0.020 |
Why?
|
Exercise Therapy | 1 | 2017 | 922 | 0.020 |
Why?
|
Brain | 1 | 2017 | 27094 | 0.020 |
Why?
|
Drug Approval | 1 | 2017 | 812 | 0.020 |
Why?
|
Fluid Shifts | 1 | 2009 | 20 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2007 | 22174 | 0.020 |
Why?
|
Calcinosis | 1 | 2018 | 1477 | 0.020 |
Why?
|
Chemokines | 1 | 2013 | 956 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2017 | 1662 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 1995 | 1838 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6819 | 0.020 |
Why?
|
Water-Electrolyte Balance | 1 | 2009 | 325 | 0.020 |
Why?
|
Glucose Transporter Type 4 | 1 | 2008 | 240 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12052 | 0.020 |
Why?
|
Bone Density | 1 | 2021 | 3546 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 3245 | 0.020 |
Why?
|
Proteins | 1 | 2003 | 5993 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2014 | 1812 | 0.020 |
Why?
|
Antioxidants | 1 | 1995 | 1667 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9319 | 0.020 |
Why?
|
Islet Amyloid Polypeptide | 1 | 2007 | 41 | 0.020 |
Why?
|
Estradiol | 1 | 2014 | 1937 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1636 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15545 | 0.020 |
Why?
|
Phosphorylation | 2 | 2008 | 8300 | 0.020 |
Why?
|
Coronary Vessels | 1 | 2017 | 3111 | 0.020 |
Why?
|
Thymidine | 1 | 2005 | 296 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 15920 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1998 | 5103 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2020 | 14392 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 7046 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 2 | 2017 | 17897 | 0.010 |
Why?
|
Organ Specificity | 1 | 2008 | 1963 | 0.010 |
Why?
|
Alleles | 1 | 2014 | 6857 | 0.010 |
Why?
|
Neutrophils | 1 | 1995 | 3763 | 0.010 |
Why?
|
Chromans | 1 | 2003 | 117 | 0.010 |
Why?
|
Mental Health | 1 | 2017 | 3251 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2011 | 1893 | 0.010 |
Why?
|
Mortality | 1 | 2014 | 2896 | 0.010 |
Why?
|
Anthropometry | 1 | 2007 | 1338 | 0.010 |
Why?
|
Glyburide | 1 | 2003 | 116 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2023 | 11476 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9652 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 2003 | 522 | 0.010 |
Why?
|
Signal Transduction | 2 | 2020 | 23419 | 0.010 |
Why?
|
Infant | 2 | 2021 | 36170 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18222 | 0.010 |
Why?
|
Molecular Weight | 1 | 2003 | 2171 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2005 | 1240 | 0.010 |
Why?
|
Child, Preschool | 2 | 2021 | 42225 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15721 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2012 | 3571 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20118 | 0.010 |
Why?
|
Mitosis | 1 | 2005 | 1187 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2455 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12985 | 0.010 |
Why?
|
Coronary Disease | 1 | 2014 | 5921 | 0.010 |
Why?
|
Genetic Variation | 1 | 2014 | 6567 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15841 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2003 | 2263 | 0.010 |
Why?
|
Logistic Models | 1 | 2013 | 13249 | 0.010 |
Why?
|
Chromogranin A | 1 | 1998 | 47 | 0.010 |
Why?
|
PC12 Cells | 1 | 1998 | 317 | 0.010 |
Why?
|
Electrocardiography | 1 | 2011 | 6387 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12676 | 0.010 |
Why?
|
Mental Disorders | 1 | 2017 | 6823 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29688 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16575 | 0.010 |
Why?
|
Carmustine | 1 | 1995 | 137 | 0.010 |
Why?
|
Thiazoles | 1 | 2003 | 1517 | 0.010 |
Why?
|
Granulomatous Disease, Chronic | 1 | 1995 | 173 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20588 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10759 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1998 | 2175 | 0.010 |
Why?
|
Glutathione | 1 | 1995 | 581 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81330 | 0.010 |
Why?
|
Cattle | 1 | 1998 | 3818 | 0.010 |
Why?
|
DNA | 1 | 2005 | 7189 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2005 | 18927 | 0.010 |
Why?
|
HIV Infections | 1 | 1995 | 17348 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1998 | 13402 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1998 | 17598 | 0.000 |
Why?
|
Rats | 1 | 1998 | 23705 | 0.000 |
Why?
|
Models, Biological | 1 | 1998 | 9458 | 0.000 |
Why?
|